Peptide holds promise of new therapeutic approach
A nasal spray that delivers a peptide to treat depression holds promise as a potential alternative therapeutic approach, research from the Centre for Addiction and Mental Health (CAMH) shows.
The study, led by CAMH’s Dr. Fang Liu, is published online in Neuropsychopharmacology.
In a previous study published in Nature Medicine in 2010, Dr. Liu developed a protein peptide that provided a highly targeted approach to treating depression that she hopes will have minimal side effects. The peptide was just as effective in relieving symptoms when compared to a conventional antidepressant in animal testing. However, the peptide had to be injected into the brain. Taken orally, it would not cross the blood-brain barrier in sufficient concentrations.
“Clinically, we needed to find a non-invasive, convenient method to deliver this peptide treatment,” says Dr. Liu, Senior Scientist in the Campbell Family Mental Health Research Institute at CAMH. With the support of a Proof of Principle grant from the Canadian Institutes of Health Research (CIHR), Dr. Liu’s team was able to further explore novel delivery methods.
The nasal delivery system, developed by U.S. company Impel NeuroPharma, was shown to deliver the peptide to the right part of the brain. It also relieved depression-like symptoms in animals.
“This study marks the first time a peptide treatment has been delivered through nasal passageways to treat depression,” says Dr. Liu, Professor in the University of Toronto’s Department of Psychiatry.
The peptide treatment interferes with the binding of two dopamine receptors – the D1 and D2 receptor complex. Dr. Liu’s team had found that this binding was higher in the brains of people with major depression. Disrupting the binding led to the anti-depressant effects.
The peptide is an entirely new approach to treating depression, which has previously relied on medications that primarily block serotonin or norepinephrine transporters.
Depression, the most common form of mental illness, is one of the leading causes of disability globally. More than 50 per cent of people living with depression do not respond to first-line medication treatment.
“This research brings us one step closer to clinical trials,” says Dr. Liu. In ongoing lab research, her team is experimenting to determine if they can make the peptide break down more slowly, and travel more quickly in the brain, to improve its anti-depressant effects.
The Latest on: Depression
via Google News
The Latest on: Depression
- Small businesses are seeing the biggest shift in how we shop since the Great Depression. Here's how entrepreneurs can reach the morally minded, Instagram-oriented customer.on November 28, 2020 at 5:30 am
This holiday season, consumers are shopping differently, using their dollars to reflect their values and have a greater impact. Experts argue that just as one day in the year doesn't define a ...
- Biogen bets on depression drug in $1.5 billion deal with Sage Therapeuticson November 27, 2020 at 3:31 pm
Biogen Inc will take a $650 million stake in Sage Therapeutics and make an upfront payment of $875 million to jointly develop and sell treatments for depression and other neurological disorders, the ...
- Biogen makes risky bet on trial depression drugon November 27, 2020 at 2:58 pm
The $1.5 billion deal with Sage Therapeutics will try to salvage an oral treatment that had a disappointing clinical trial ...
- Sage Gets $3 Billion Endorsement of Its Depression Drugs From Biogenon November 27, 2020 at 12:25 pm
Shaken by a government advisory panel’s poor review of its experimental treatment for Alzheimer’s disease, Biogen announced a team-up Friday with Sage Therapeutics. Biogen has committed up to $3.1 ...
- Sage to Get $1.53 Billion From Biogen for Depression Drug Developmenton November 27, 2020 at 9:42 am
The companies will develop Sage’s zuranolone for major depressive disorder, postpartum depression and other psychiatric disorders.
- Depression-Era Secrets of Retail Survivalon November 27, 2020 at 5:17 am
In the early 20th century, independent stores dominated retail storefronts in cities and towns across the nation. Most Americans bought everything from books to meats to gardening supplies from ...
- After Cyclone Nivar, another low depression forming in Bay of Bengal, to intensify by Sundayon November 27, 2020 at 12:51 am
The Indian Meteorological Department (IMD) in Chennai has sounded a caution bell over another low depression forming in the Bay of Bengal, less than two days after Cyclone Nivar disrupted normal life ...
- Chrissy Teigen Says She's in a ‘Grief Depression Hole' Weeks After Pregnancy Losson November 26, 2020 at 11:31 pm
It’s been nearly two months since Chrissy Teigen and John Legend revealed their heartbreaking news: At 20 weeks pregnant, Teigen suffered pregnancy complications that resulted in the loss of the child ...
- Chrissy Teigen talks post-miscarriage depressionon November 26, 2020 at 2:11 pm
Model and TV personality Chrissy Teigen, who with her singer husband John Legend suffered a miscarriage on Sept. 30, continues to struggle in the aftermath. "I'm not tweeting much because I'm honestly ...
- Chrissy Teigen is in 'grief depression hole'on November 26, 2020 at 7:12 am
Once again Chrissy Teigen is being open about her struggles. On Wednesday the usually prolific social media user tweeted as to why she has not been around as much. "I'm not tweeting much because I'm ...
via Bing News